Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/

Takeshi Mori, Novotech Country Head, Japan

The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, FDA-aligned protocol development, US-based scientific expertise, and international partnering opportunities.

Japan is one of the world’s largest and most advanced pharmaceutical markets, supported by a sophisticated research base and a rapidly evolving biotech sector. As more Japanese biopharma companies look to expand beyond domestic development and bring novel therapies to global markets, Novotech’s expanded presence in Tokyo strengthens its ability to support cross-border clinical trials and connect sponsors across Asia-Pacific, the United States, and Europe.

Novotech’s global operating model is particularly well aligned to the needs of emerging and growth-stage biopharma companies, providing flexible, high-quality clinical development support without the complexity of managing multiple regional providers. The company brings deep experience across therapeutic areas including oncology, rare diseases, central nervous system disorders, infectious diseases, immunology, and advanced therapies, supported by strong regulatory, scientific, and operational expertise across major clinical trial markets.

Takeshi Mori, Country Head, Japan, commented:
“The opening of our Tokyo office is an important milestone for Novotech. Japan is a critical market for global clinical development, and this investment reflects our long-term commitment to building strong local capabilities while delivering high-quality services to our clients.”

The office is located at:
27F Shinjuku i-Land Tower, 6-5-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan 163-1327

The opening of the Tokyo office builds on Novotech’s established presence in Japan and reflects its broader strategy to strengthen its global footprint and position itself as a leading CRO partner for biotech companies worldwide.

About Novotech Novotech-CRO.com

Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase.

With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 7,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations.

Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide.

Recipient of numerous industry accolades, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies.

Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results

For more information or to speak to an expert team member visit www.Novotech-CRO.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260823592174/en/

Media Contact
Toyna Chin
mediacontact@novotech-cro.com
USA: +1 415 364 8135

Logo

Images

Tags

More Like This

Novotech Executive Team at J.P. Morgan Healthcare Conference: Global CRO Designed for Biotechs Across 25 Regions

Novotech Honored with Frost & Sullivan’s 2024 Best Practices Company of the Year Award for Leadership in Biotech CRO Services

Novotech Named Best Contract Research Organization in Australia at Asia-Pacific Biopharma Excellence Awards 2025

Frost & Sullivan Recognizes Novotech as 2025 Global Biotech CRO Company of the Year

Novotech Recognized for Excellence in Business Expansion, Innovation, and Marketing at the 2024 Clinical Trials Arena Excellence Awards

Novotech Secures Consecutive Frost & Sullivan CRO Company of the Year Award

New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration

Novotech Named a Fierce CRO Award Winner in the Excellence in Clinical Trial Management and Global Operations Categories